Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference
Rhea-AI Summary
Revelation Biosciences (NASDAQ:REVB) will participate in the 38th Annual Roth Conference in Dana Point, CA, on March 23–24, 2026. CEO James Rolke and CFO Chester S. Zygmont III will attend, and the company will hold a fireside chat on March 24, 2026 at 2:00 p.m. PT.
The fireside chat will be webcast live and later posted in the Investors section at www.RevBiosciences.com. Investors seeking meetings should contact their Roth representative.
Positive
- None.
Negative
- None.
News Market Reaction – REVB
In the Mar 19 session, REVB declined 1.64%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 26 | Earnings and update | Positive | -0.8% | Year-end 2025 results, cash runway into Q1 2027, Gemini clinical progress. |
| Jan 26 | Reverse stock split | Negative | -14.8% | 1-for-4 reverse split to address Nasdaq minimum bid listing requirement. |
| Jan 23 | Warrant inducement deal | Negative | -24.4% | Immediate exercise of warrants for ~$11M gross proceeds and new Class J warrants. |
| Jan 21 | FDA pathway agreement | Positive | -10.1% | FDA agreement on single adaptive Phase 2/3 Gemini study in AKI (~300 patients). |
| Jan 14 | Conference data presentation | Positive | -0.6% | PRIME study data on Gemini at critical care nephrology conference in San Diego. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent REVB news, including positive clinical and regulatory updates, has often been followed by negative price reactions, and dilutive or structural actions like splits and warrant deals have also coincided with selling.
Over the last few months, REVB has combined financing, structural actions, and clinical progress. A Jan 23, 2026 warrant inducement generated roughly $11M but saw a sharp selloff. A 1-for-4 reverse split on Jan 28 also drew a negative reaction. In parallel, the company reached an FDA agreement for a single Phase 2/3 Gemini study and reported PRIME data, yet those positives were met with modest declines. Today’s conference fireside chat fits into this ongoing visibility and outreach effort.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, CA / ACCESS Newswire / March 19, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, announced today that James Rolke, Revelation's Chief Executive Officer, and Chester S. Zygmont, III, Revelation's Chief Financial Officer, will be attending the 38th Annual Roth Conference, in Dana Point, CA, on Monday and Tuesday March 23rd and 24th. On Tuesday, March 24, 2026, at 2:00 p.m. PT, the Company will participate in a fireside chat.
The fireside chat will be webcast live here and available on our Investors section of the Revelation Biosciences website, www.RevBiosciences.com, after the meeting.
Investors who wish to schedule a meeting with Revelation's management during the conference should contact their Roth representative.
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a clinical-stage life sciences company focused on rebalancing inflammation using its proprietary formulation, Gemini. Revelation has multiple ongoing programs to evaluate Gemini as a treatment for acute kidney injury, a treatment of chronic kidney disease, prevention of post-surgical infection, and a treatment to reduce hyperinflammation and infection associated with severe burn.
For more information, please visit www.RevBiosciences.com.
Company Contacts
Mike Porter
Investor Relations
Porter LeVay & Rose Inc.
Email: mike@plrinvest.com
Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com
SOURCE: Revelation Biosciences, Inc.
View the original press release on ACCESS Newswire